These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 25754490)

  • 1. trans-3,4-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part II: prime site exploration using an oxygen linker.
    Sellner H; Cottens S; Cumin F; Ehrhardt C; Kosaka T; Lorthiois E; Ostermann N; Webb RL; Rigel DF; Wagner T; Maibaum J
    Bioorg Med Chem Lett; 2015 Apr; 25(8):1787-1791. PubMed ID: 25754490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. trans-(3S,4S)-Disubstituted pyrrolidines as inhibitors of the human aspartyl protease renin. Part I: prime site exploration using an amino linker.
    Lorthiois E; Cumin F; Ehrhardt C; Kosaka T; Sellner H; Ostermann N; Francotte E; Wagner T; Maibaum J
    Bioorg Med Chem Lett; 2015 Apr; 25(8):1782-1786. PubMed ID: 25782742
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The discovery of novel potent trans-3,4-disubstituted pyrrolidine inhibitors of the human aspartic protease renin from in silico three-dimensional (3D) pharmacophore searches.
    Lorthiois E; Breitenstein W; Cumin F; Ehrhardt C; Francotte E; Jacoby E; Ostermann N; Sellner H; Kosaka T; Webb RL; Rigel DF; Hassiepen U; Richert P; Wagner T; Maibaum J
    J Med Chem; 2013 Mar; 56(6):2207-17. PubMed ID: 23425156
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Structure-based drug design: the discovery of novel nonpeptide orally active inhibitors of human renin.
    Rahuel J; Rasetti V; Maibaum J; Rüeger H; Göschke R; Cohen NC; Stutz S; Cumin F; Fuhrer W; Wood JM; Grütter MG
    Chem Biol; 2000 Jul; 7(7):493-504. PubMed ID: 10903938
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of renin inhibitors containing a simple aspartate binding moiety that imparts reduced P450 inhibition.
    Lawhorn BG; Tran T; Hong VS; Morgan LA; Le BT; Harpel MR; Jolivette L; Diaz E; Schwartz B; Gross JW; Tomaszek T; Semus S; Concha N; Smallwood A; Holt DA; Kallander LS
    Bioorg Med Chem Lett; 2017 Nov; 27(21):4838-4843. PubMed ID: 28985999
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of benzimidazole derivatives as orally active renin inhibitors: Optimization of 3,5-disubstituted piperidine to improve pharmacokinetic profile.
    Tokuhara H; Imaeda Y; Fukase Y; Iwanaga K; Taya N; Watanabe K; Kanagawa R; Matsuda K; Kajimoto Y; Kusumoto K; Kondo M; Snell G; Behnke CA; Kuroita T
    Bioorg Med Chem; 2018 Jul; 26(12):3261-3286. PubMed ID: 29754833
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design and optimization of a substituted amino propanamide series of renin inhibitors for the treatment of hypertension.
    Chen A; Bayly C; Bezençon O; Richard-Bildstein S; Dubé D; Dubé L; Gagné S; Gallant M; Gaudreault M; Grimm E; Houle R; Lacombe P; Laliberté S; Lévesque JF; Liu S; MacDonald D; Mackay B; Martin D; McKay D; Powell D; Remen L; Soisson S; Toulmond S
    Bioorg Med Chem Lett; 2010 Apr; 20(7):2204-9. PubMed ID: 20206513
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potent pyrrolidine- and piperidine-based BACE-1 inhibitors.
    Iserloh U; Wu Y; Cumming JN; Pan J; Wang LY; Stamford AW; Kennedy ME; Kuvelkar R; Chen X; Parker EM; Strickland C; Voigt J
    Bioorg Med Chem Lett; 2008 Jan; 18(1):414-7. PubMed ID: 18023580
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected novel binding mode of pyrrolidine-based aspartyl protease inhibitors: design, synthesis and crystal structure in complex with HIV protease.
    Specker E; Böttcher J; Brass S; Heine A; Lilie H; Schoop A; Müller G; Griebenow N; Klebe G
    ChemMedChem; 2006 Jan; 1(1):106-17. PubMed ID: 16892342
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structure-based design of a new series of N-(piperidin-3-yl)pyrimidine-5-carboxamides as renin inhibitors.
    Imaeda Y; Tawada M; Suzuki S; Tomimoto M; Kondo M; Tarui N; Sanada T; Kanagawa R; Snell G; Behnke CA; Kubo K; Kuroita T
    Bioorg Med Chem; 2016 Nov; 24(22):5771-5780. PubMed ID: 27687967
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A novel class of oral direct renin inhibitors: highly potent 3,5-disubstituted piperidines bearing a tricyclic p3-p1 pharmacophore.
    Ostermann N; Ruedisser S; Ehrhardt C; Breitenstein W; Marzinzik A; Jacoby E; Vangrevelinghe E; Ottl J; Klumpp M; Hartwieg JC; Cumin F; Hassiepen U; Trappe J; Sedrani R; Geisse S; Gerhartz B; Richert P; Francotte E; Wagner T; Krömer M; Kosaka T; Webb RL; Rigel DF; Maibaum J; Baeschlin DK
    J Med Chem; 2013 Mar; 56(6):2196-206. PubMed ID: 23360239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Renin inhibitors for the treatment of hypertension: design and optimization of a novel series of spirocyclic piperidines.
    Chen A; Aspiotis R; Campeau LC; Cauchon E; Chefson A; Ducharme Y; Falgueyret JP; Gagné S; Han Y; Houle R; Laliberté S; Larouche G; Lévesque JF; McKay D; Percival D
    Bioorg Med Chem Lett; 2011 Dec; 21(24):7399-404. PubMed ID: 22071301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. X-ray structures of five renin inhibitors bound to saccharopepsin: exploration of active-site specificity.
    Cronin NB; Badasso MO; J Tickle I; Dreyer T; Hoover DJ; Rosati RL; Humblet CC; Lunney EA; Cooper JB
    J Mol Biol; 2000 Nov; 303(5):745-60. PubMed ID: 11061973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comprehending renin inhibitor's binding affinity using structure-based approaches.
    Subramanian G; Rao SN
    Bioorg Med Chem Lett; 2013 Dec; 23(24):6667-72. PubMed ID: 24239018
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel approach of fragment-based lead discovery applied to renin inhibitors.
    Tawada M; Suzuki S; Imaeda Y; Oki H; Snell G; Behnke CA; Kondo M; Tarui N; Tanaka T; Kuroita T; Tomimoto M
    Bioorg Med Chem; 2016 Nov; 24(22):6066-6074. PubMed ID: 27720325
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Synthesis and optimization of novel (3S,5R)-5-(2,2-dimethyl-5-oxo-4-phenylpiperazin-1-yl)piperidine-3-carboxamides as orally active renin inhibitors.
    Mori Y; Ogawa Y; Mochizuki A; Nakamura Y; Fujimoto T; Sugita C; Miyazaki S; Tamaki K; Nagayama T; Nagai Y; Inoue S; Chiba K; Nishi T
    Bioorg Med Chem; 2013 Sep; 21(18):5907-22. PubMed ID: 23886807
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimization of orally bioavailable alkyl amine renin inhibitors.
    Xu Z; Cacatian S; Yuan J; Simpson RD; Jia L; Zhao W; Tice CM; Flaherty PT; Guo J; Ishchenko A; Singh SB; Wu Z; McKeever BM; Scott BB; Bukhtiyarov Y; Berbaum J; Mason J; Panemangalore R; Cappiello MG; Bentley R; Doe CP; Harrison RK; McGeehan GM; Dillard LW; Baldwin JJ; Claremon DA
    Bioorg Med Chem Lett; 2010 Jan; 20(2):694-9. PubMed ID: 19959358
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-based optimization of potent 4- and 6-azaindole-3-carboxamides as renin inhibitors.
    Scheiper B; Matter H; Steinhagen H; Böcskei Z; Fleury V; McCort G
    Bioorg Med Chem Lett; 2011 Sep; 21(18):5480-6. PubMed ID: 21840218
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design, synthesis and evaluation of novel sulfonyl pyrrolidine derivatives as matrix metalloproteinase inhibitors.
    Cheng XC; Wang Q; Fang H; Tang W; Xu WF
    Bioorg Med Chem; 2008 May; 16(10):5398-404. PubMed ID: 18440232
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery of an orally efficaceous 4-phenoxypyrrolidine-based BACE-1 inhibitor.
    Iserloh U; Pan J; Stamford AW; Kennedy ME; Zhang Q; Zhang L; Parker EM; McHugh NA; Favreau L; Strickland C; Voigt J
    Bioorg Med Chem Lett; 2008 Jan; 18(1):418-22. PubMed ID: 17980584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.